Anne Roshan Joseph

Varnimcabtagene autoleucel in relapsed or refractory B-cell malignancies

Sharat Damodar, Sunil Jee Bhat, Raja Thirumalairaj, Pankaj Malhotra et autres

Varnimcabtagene autoleucel (varnim-cel), an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has demonstrated an antitumor activity and toxicity profile consistent with known CAR T-cell–associated adverse effects in patients with relapsed or refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and …

Varnimcabtagene Autoleucel (IMN-003A): Pharmacokinetic Profile with Predominant Naïve and Central Memory Phenotype Demonstrates Sustained In Vivo Persistence and Durable Responses in a First-in-India Industry Phase-2 Study (IMAGINE)

Sunil Bhat, Sharat Damodar, Raja Thirumalairaj, Pankaj Malhotra et autres

Background: Varnimcabtagene autoleucel (IMN-003A) is an autologous CD19 directed CAR-T cell product with a 4-1BB co-stimulatory domain and a non-FMC63 murine single chain variable fragment (A3B1 binder), manufactured in India, tested in the IMAGINE study (CTRI/2022/03/041162), a phase-2 clinical trial for patients …

in (code pays fourni par la source)

Cytokine Profile Following Varnimcabtagene Autoleucel (IMN-003A) in Patients with Relapsed Refractory B Cell Malignancies in the First-in-India Industry Phase-2 Study (IMAGINE)

Sharat Damodar, Sunil Jee Bhat, Raja Thirumalairaj, Pankaj Malhotra et autres

Background: Varnimcabtagene autoleucel (Var-cel, IMN-003A) is an autologous CD19 directed CAR-T cell product with a 4-1BB co-stimulatory domain and a non-FMC63 murine single chain variable fragment (A3B1 binder), manufactured in India, tested in the IMAGINE study (CTRI/2022/03/041162), a phase-2 clinical trial for …

in (code pays fourni par la source)

Varnimcabtagene Autoleucel (IMN-003A): Differences in T Cell Subset Phenotype in B-ALL and B-NHL Cohorts Did Not Influence Efficacy Outcomes in the Phase-2 Study (IMAGINE)

Sunil Bhat, Sharat Damodar, Raja Thirumalairaj, Pankaj Malhotra et autres

Background: Varnimcabtagene autoleucel (IMN-003A) is an autologous CD19 directed CAR-T cell product with a 4-1BB co-stimulatory domain and a non-FMC63 murine single chain variable fragment (A3B1 binder), manufactured in India, tested in the IMAGINE study (CTRI/2022/03/041162), a phase-2 clinical trial for patients …

in (code pays fourni par la source)

P1364: PHARMACOKINETIC PROFILE OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A), FIRST-IN-INDIA INDUSTRY CD19-DIRECTED CAR-T CELL THERAPY FOR PATIENTS WITH RELAPSED/ REFRACTORY B CELL MALIGNANCIES (IMAGINE STUDY)

Pankaj Malhotra, Sunil Bhat, Sharat Damodar, Raja Thirumalairaj et autres

Topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research Background: Varnimcabtagene autoleucel (IMN-003A) is an autologous CD19 directed CAR-T cell product with a 4-1BB co-stimulatory domain and A3B1 binder, a non-FMC63 murine single chain variable fragment, manufactured in …

in (code pays fourni par la source)

Immunotherapy: IMAGINE STUDY: INTERIM TRANSLATIONAL OUTCOMES OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A) FROM FIRST-IN-INDIA PHASE 2 TRIAL FOR ANTI CD19-CAR-T CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES

S. Bhat, Sharat Damodar, R. Thirumalairaj, Pankaj Malhotra et autres

Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)

Sunil Jee Bhat, Sharat Damodar, Pooja P. Mallya, Akshatha Nayak et autres

Background: Varnimcabtagene autoleucel (IMN-003A) is an autologous CD19 directed CAR-T cell product with a 4-1BB co-stimulatory domain and a non-FMC63 murine single chain variable fragment (A3B1 binder), manufactured in India, which is being tested in the IMAGINE study (CTRI/2022/03/041162), a phase-2 clinical …

in (code pays fourni par la source)

Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)

Sharat Damodar, Sunil Jee Bhat, Akshatha Nayak, Pooja P. Mallya et autres

Background: Varnimcabtagene autoleucel (IMN-003A) is an autologous second-generation CAR T-cell product with a 4-1BB co-stimulatory domain and a non-FMC63 based murine single chain variable fragment targeting CD19 (A3B1 binder), manufactured in India. As previously published, pre-clinical studies and phase 1 clinical trial …

in (code pays fourni par la source)